Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: RFA-NS-27-007
Official listed status: posted
Closing information: 2029-02-20 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: Independent school districts; Native American tribal governments (Federally recognized); For profit organizations other than small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Special district governments; County governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); Public and State controlled institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); City or township governments; Public housing authorities/Indian housing authorities; Private institutions of higher education; State governments
Federal synopsis
The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain. The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope of the program includes lead optimization, early-stage development activities, IND-enabling studies, development of pharmacodynamic and/or target engagement biomarkers, preparation and submission of an Investigational New Drug (IND) application, and Phase I clinical testing. This is a milestone-driven, phased cooperative agreement program that involves active participation by NIH program staff in project planning and ongoing monitoring of research progress.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.